- Bradford A. Young, Ph.D., MBA was recently appointed senior vice president and chief commercial officer
- A very accomplished and experienced businessman and scientist, Young has helped guide and grow both startups and large companies
- Young is expected to leverage his technical expertise and real-world experience to drive revenue growth via major partnerships and new commercialization programs
A leader in the development and commercialization of innovative, pressure-based technologies for the worldwide life sciences industry, Pressure BioSciences Inc. (OTCQB: PBIO) recently appointed Dr. Bradford A. Young as its senior vice president and chief commercial officer. The move is designed to help drive the company’s revenue growth and expand its commercialization programs by leveraging Young’s experience as both a scientist and a well-connected and experienced businessman.
Speaking about the appointment during a recent Uptick Newswire Stock Day Podcast with Everett Jolly (http://ibn.fm/Yw0lD), Pressure BioSciences CEO Richard T. Schumacher praised Young for his many accomplishments, as well as his academic and entrepreneurial background. Young has a Ph.D. in biochemistry from the University of Maryland School of Medicine and an MBA from the University of California, Berkeley, Haas School of Business.
“He is quite a fellow. I’ve known him personally and professionally for over six years. (…) He combines the acumen, skills and experience of someone who has had both entrepreneurial as well as big company experience,” the Pressure BioSciences CEO noted in the interview.
Young joins the Pressure BioSciences management team with a solid entrepreneurial background and the experience of providing executive level consulting for strategic planning, product development and commercialization to various biomedical, diagnostic and pharmaceutical companies. In his new position as senior vice president and chief commercial officer, he will play a critical role in advancing the company’s commercialization programs and overall strategic planning, with a view toward establishing new and/or enhanced revenue opportunities and significant partnerships.
More specifically, Young will promote the company’s instruments, consumables and technology platforms with synergistic companies worldwide, with a goal of integrating Pressure BioSciences’ products into their offerings. These types of collaborations and partnerships could result in major volume sales, enabling the company to significantly boost its revenue.
“Dr. Young will be designing and implementing PBI’s commercial programs, including business development. He will be working with many companies that we believe should be and could be offering our sample preparation systems together with their own analytical instrumentation,” Schumacher said during the Stock Day Podcast. “We think this type of collaboration will let one plus one equal three. Our instruments are used to break apart samples to prepare them to be tested, while the companies he will be speaking with offer the analytical equipment that is used to test the samples. It makes total sense to put our sample preparation systems together with their analytical instruments.”
In addition to accelerating revenue growth via critical partnerships and new commercialization programs, Young will also assess multiple opportunities for expansion into new and divergent markets, optimize commercialization priorities and work to advance customer adoption.
Before joining Pressure BioSciences, Young held a number of management positions with both large and small companies, including founder and CEO of AddisonField Corporation, a biotech company developing consumer health products; vice president of business development for Nodality, a pharmaceutical services provider offering disease and drug profiling in autoimmune diseases and oncology; director of market and business development for Quest Diagnostics (NYSE: DGX), one of the largest clinical reference laboratories in the U.S.; and head of market development with Celera, a personalized medicine pioneer. He also serves on the board of directors of circulating tumor cell diagnostics company Liquid Biotech, Inc., and is a selection committee member for the Stanford Predictive and Diagnostics Accelerator program.
In a recent news release announcing his appointment (http://ibn.fm/tuajI), Young voiced excitement in joining the Pressure BioSciences team at a time when he can help develop and lead commercial strategies designed to promote the company’s patented, pressure-based technology platforms while working to enhance adoption rates and sales.
“I look forward to leading the company’s commercialization and strategic partnership efforts in its highly-respected core area of pressure cycling technology (PCT) products, as well as its recently acquired PreEMT platform for improving the development of protein therapeutics. I am particularly excited to become part of PBI’s team that is developing the Company’s powerful new Ultra Shear Technology (”UST”) platform. I believe that UST can open up a vast range of market opportunities for nano-scale emulsions, including in the nutraceuticals (e.g., CBD oil), cosmetics, pharmaceuticals, and food industries,” he said.
For more information, visit the company’s website at www.PressureBioSciences.com
